
Sign up to save your podcasts
Or


Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets Darovasertib, a DLL3 ADC, MAT2A, and more.
By BiotechTV5
44 ratings
Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets Darovasertib, a DLL3 ADC, MAT2A, and more.

30,636 Listeners

1,872 Listeners

1,086 Listeners

325 Listeners

6,086 Listeners

60 Listeners

9,852 Listeners

86 Listeners

34 Listeners

19 Listeners

260 Listeners

500 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners